Imaging Biometrics Ltd (IBAI) RNS Announcements

Add to Alert list
Date Time Source Announcement
05 Aug 2019 02:00 PM
RNS
Price Monitoring Extension
09 Jul 2019 07:00 AM
RNS
Update on Gadolinium Free Imaging Project
26 Jun 2019 07:00 AM
RNS
Placing
24 Jun 2019 02:52 PM
RNS
Holding(s) in Company
20 Jun 2019 04:40 PM
RNS
Second Price Monitoring Extn
20 Jun 2019 04:35 PM
RNS
Price Monitoring Extension
12 Jun 2019 07:00 AM
RNS
Business Development Agreement with CorTechs Labs
06 Jun 2019 11:49 AM
RNS
Result of AGM
29 May 2019 11:51 AM
RNS
Issue of Convertible Loan Notes - Correction
29 May 2019 08:22 AM
RNS
Issue of Convertible Loan Notes
17 May 2019 12:00 PM
RNS
Extension of Loan Notes Redemption Date
09 May 2019 01:30 PM
RNS
Notice of AGM
09 May 2019 12:13 PM
RNS
Holding(s) in Company
30 Apr 2019 12:00 PM
RNS
Publication of Annual Report
02 Apr 2019 07:00 AM
RNS
Imaging Biometrics Update
11 Mar 2019 07:00 AM
RNS
Issue of Convertible Loan Notes
08 Feb 2019 10:29 AM
RNS
Business Update
02 Jan 2019 12:20 PM
RNS
Holding(s) in Company
13 Dec 2018 09:00 AM
RNS
Price Monitoring Extension
13 Dec 2018 07:00 AM
RNS
StoneChecker 510k Update
11 Dec 2018 07:00 AM
RNS
Installation at Barrow Neurological Institute
28 Nov 2018 07:00 AM
RNS
Imaging Biometrics® Update
16 Nov 2018 07:00 AM
RNS
First Commercial Sale of StoneChecker Software
22 Oct 2018 07:00 AM
RNS
IQ-AI files patent for Contrast-Free Imaging
04 Oct 2018 02:58 PM
RNS
Result of EGM and Change of Name
27 Sep 2018 07:00 AM
RNS
IB announce agreement to develop a diagnostic tool
18 Sep 2018 07:00 AM
RNS
Proposed name change and notice of EGM
11 Sep 2018 09:00 AM
RNS
Director/PDMR Shareholding
11 Sep 2018 07:00 AM
RNS
Director/PDMR Shareholding
10 Sep 2018 07:00 AM
RNS
Half-year Report
06 Aug 2018 02:51 PM
RNS
Holding(s) in Company
06 Aug 2018 10:16 AM
RNS
Holding(s) in Company
06 Aug 2018 07:00 AM
RNS
Appointment of CEO to the Operating Subsidiaries
01 Aug 2018 04:28 PM
RNS
Publication of a Prospectus

IQ-AI Ltd operates as an investment company. The principal activity of the group is the provision of convenient, cost-effective, and clinical treatments to patients in the field of medical imaging diagnostics, based on proven technologies. Its geographical segment includes Jersey and the United States of America and reportable segments are holding company expenses and medical software. The company derives a majority of revenue from the United States of America. It also supplies medical technology solutions and has a strong neuroimaging product portfolio.

IQ-AI share price listed in London at 87p in 1996.

UK 100

Latest directors dealings